| Author, year | Study design | Population | Intervention | Outcomes | SMD (CI 95%) |
|
|
| Treatment/Placebo |
|
|
|
| Aarsland, 2001 | Clinical trial | 6/6 | Donepezil 10 mg/Placebo | MMSE | 0.41 (−0.73 to 1.55) |
| Leroi, 2003 | Clinical trial | 7/9 | Donepezil 10 mg/Placebo | MMSE | 0.21 (−0.78 to 1.2) |
| Emre, 2004 | Clinical trial | 362/179 | Rivastigmine 12 mg/Placebo | MMSE Adas-Cog | 0.18 (−0.00 to 0.37) 0.29 (0.10 to 0.48) |
| Ravina, 2005 | Clinical trial | 11/11 | Donepezil 10 mg/Placebo | MMSE Adas-Cog | 0.07 (−0.82 to 0.97) 0.11 (−0.79 to 1.00) |
| Dubois, 2012 | Clinical trial | 182/173 | Donepezil 10 mg/Placebo | MMSE Adas-Cog | 0.34 (0.13 to 0.55) 0.11 (−0.10 to 0.32) |